OPKO Health (NASDAQ:OPK) Upgraded at Wall Street Zen

by · The Markets Daily

Wall Street Zen upgraded shares of OPKO Health (NASDAQ:OPK – Free Report) from a sell rating to a hold rating in a report released on Sunday.

Several other research analysts also recently weighed in on OPK. Weiss Ratings restated a “sell (d-)” rating on shares of OPKO Health in a research note on Wednesday, October 8th. JPMorgan Chase & Co. assumed coverage on shares of OPKO Health in a report on Thursday, November 20th. They issued a “neutral” rating on the stock. Jefferies Financial Group restated a “hold” rating and set a $1.60 target price (down from $2.00) on shares of OPKO Health in a research note on Thursday, October 30th. Finally, Barrington Research reaffirmed an “outperform” rating and set a $2.25 target price on shares of OPKO Health in a research report on Thursday, October 30th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $2.28.

Get Our Latest Stock Analysis on OPKO Health

OPKO Health Price Performance

OPK stock opened at $1.31 on Friday. The firm has a market cap of $1.01 billion, a P/E ratio of -5.24 and a beta of 1.34. The company has a debt-to-equity ratio of 0.25, a quick ratio of 3.32 and a current ratio of 3.70. OPKO Health has a 1 year low of $1.11 and a 1 year high of $2.04. The stock has a 50-day simple moving average of $1.37 and a 200-day simple moving average of $1.38.

OPKO Health (NASDAQ:OPK – Get Free Report) last released its quarterly earnings results on Wednesday, October 29th. The biotechnology company reported $0.03 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.05. OPKO Health had a negative return on equity of 13.67% and a negative net margin of 28.10%.The firm had revenue of $151.67 million for the quarter, compared to analyst estimates of $165.74 million. During the same period in the previous year, the company posted $0.03 EPS. OPKO Health’s revenue for the quarter was down 12.6% on a year-over-year basis. On average, equities analysts predict that OPKO Health will post -0.25 earnings per share for the current fiscal year.

Insider Activity

In related news, CEO Phillip Md Et Al Frost purchased 580,000 shares of OPKO Health stock in a transaction dated Friday, November 21st. The shares were acquired at an average price of $1.33 per share, with a total value of $771,400.00. Following the completion of the transaction, the chief executive officer owned 216,706,448 shares of the company’s stock, valued at approximately $288,219,575.84. This trade represents a 0.27% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last quarter, insiders have bought 1,843,300 shares of company stock valued at $2,421,491. Corporate insiders own 49.69% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Sculptor Capital LP bought a new stake in shares of OPKO Health in the 1st quarter worth approximately $21,111,000. Graham Capital Management L.P. increased its position in OPKO Health by 214.7% in the first quarter. Graham Capital Management L.P. now owns 1,810,392 shares of the biotechnology company’s stock worth $3,005,000 after buying an additional 3,388,292 shares during the period. Geode Capital Management LLC increased its position in OPKO Health by 23.7% in the second quarter. Geode Capital Management LLC now owns 10,424,473 shares of the biotechnology company’s stock worth $13,763,000 after buying an additional 1,995,633 shares during the period. Millennium Management LLC lifted its stake in OPKO Health by 39.2% in the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock valued at $10,602,000 after buying an additional 1,798,385 shares during the last quarter. Finally, Nuveen LLC acquired a new position in shares of OPKO Health during the first quarter valued at $2,286,000. Institutional investors own 64.63% of the company’s stock.

About OPKO Health

(Get Free Report)

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.

Recommended Stories